Pfizer Says No To "Fee-For-Service" Contracts With Wholesalers
This article was originally published in The Pink Sheet Daily
Executive Summary
The manufacturer maintains that wholesalers "purchase and resell products for their own account and not as a service to Pfizer." Cardinal will no longer distribute Eisai products, including the Alzheimer's drug Aricept, marketed in partnership with Pfizer.
You may also be interested in...
McKesson In Final Phase Of Negotiating Fee-For-Service Contracts
The wholesaler anticipates 80% of compensation from manufacturers will be recorded under the new contract model by Oct. 1. Pfizer continues to be a significant holdout within the transition to fee-for-service, McKesson says.
McKesson In Final Phase Of Negotiating Fee-For-Service Contracts
The wholesaler anticipates 80% of compensation from manufacturers will be recorded under the new contract model by Oct. 1. Pfizer continues to be a significant holdout within the transition to fee-for-service, McKesson says.
Cardinal Sees No Rx Distribution Disruptions After April 1 Fee-For-Service Deadline
Most drug manufacturers have agreed in principle to fee-for-service distribution contracts, Cardinal CEO Walter says. Negotiations are now focused on price, not the methodology for paying wholesalers, he says.